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A B S T R A C T
Objective: Breakthrough cancer pain (BTCP) represents a considerable economic burden. A
decision-analysis model was developed to evaluate the cost-effectiveness of intranasal
fentanyl spray (INFS) comparedwith oral transmucosal fentanyl citrate (OTFC) and fentanyl
buccal tablet (FBT) for the treatment of BTCP.
Methods: The model was parameterized for Sweden to estimate the costs and benefits
associated with treatments. Expected reductions in pain intensity (PI; measured on a nu-
meric rating scale ranging from 0 to 10) per BTCP episodes were translated into resource use
and quality-adjusted life years (QALYs). Relative analgesic efficacy of interventions was
derived from a mixed treatment comparison of six randomized controlled trials. The rela-
tionship between PI and utility was obtained from a time-trade off study in the general
population. Resource use and unit cost datawere obtained from the literature and validated
by Swedish clinical experts. The base case scenario assumed three BTCP episodes/day, a
background PI of 2, and a time horizon of 180 days. Prices of INFS and OTFC were assumed
to be equal with FBT 14% less. Uncertainty in the source data was incorporated by proba-
bilistic sensitivity analyses and different scenario analyses.
Results: With INFS, 55% of BTCP (95%uncertainty interval [UI]: 46–68%)was avoided,which
is greater than expected with OTFC (29%; UI 22–38%) or FBT (31%; UI 25–39%). INFS was
dominating OTFC (resulting in 0.046 QALY gain and saving 174 Euros with a time horizon of
180 days) and cost-effective versus FBT (incremental cost-effectiveness ratio 12203 Euros/
QALY). Despite uncertainty in the source data, there is a 99% probability that INFS is the
most cost-effective intervention.
Conclusion: Given inherent limitations of modelling studies, the greater efficacy of INFS
translates to cost and QALY advantages over competing interventions in the treatment for
BTCP in Sweden.
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Breakthrough cancer pain (BTCP) is defined as a transitory
exacerbation of pain experienced by a patient who has rela-
tively stable and adequately controlled background pain [1].
he clinical features of BTCP can vary considerably, both be-
ween andwithin individuals. However, it is generally charac-
erized by its fast onset, short duration, and unpredictable but
requent occurrence. In a recent survey, the number of BTCP
pisodes ranged from one to eight per day, and the average
urationwas 35minutes (range, 15–60minutes) [2]. In another
tudy, the majority of episodes lasted for less than 1 hour [3].
TCP has been reported to occur in 24% to 95% of patientswith
ancer, with the wide variation in prevalence attributable to
he use of different definitions for BTCP and differences in
linical settings [4,5].
BTCP is associated with considerable morbidity, and has
egative physical, psychological, and social consequences.
atients with BTCP have more severe chronic pain, impaired
hysical function, increased levels of anxiety and depression,
nd more dissatisfaction with opioid treatment [6–8]. As a
esult, BTCP results in a significantly impaired quality of life
9]. The occurrence of BTCP also represents a considerable
conomic burden, although this has not beenwell studied [10].
n a US survey of 1000 patients with cancer, those with BTCP
ncurred higher direct medical costs due to increased occur-
ence of pain-related hospitalizations, emergency room (ER)
isits, and physician office visits compared with patients
ithout BTCP [11]. In another US-based survey of 373 cancer
utpatients, BTCP was shown to predict higher indirect costs
e.g., transport costs, extra household assistance) as well as
irect medical costs [12].
Oral opioids are the usual treatment for BTCP. Although
ot indicated for BTCP, normal-release morphine sulphate is
he most widely used, with other short-acting opioids (e.g.,
xycodone, hydromorphone) also sometimes prescribed.
owever, the clinical characteristics of these treatments do
ot match the typical BTCP episode. Oral ingestion of opioids
s associated with a delay in both onset of action and peak
nalgesic effect, resulting in inadequate pain control during
he first 30 minutes of a BTCP episode [13]. In addition, their
uration of effect may be longer than required, resulting in an
ncreased risk of opioid-related adverse effects.
These limitations have encouraged the search for new
reatment options that better reflect the temporal character-
stics of BTCP, having a fast onset of action and a short dura-
ion of effect. Unlike morphine, the opioid fentanyl is highly
ipophilic and is rapidly absorbed across the mucosal surface,
esulting in a faster onset of action. The first fentanyl formu-
ation specifically developed to treat BTCP was oral transmu-
osal fentanyl citrate (OTFC; Actiq, Cephalon, Frazer, PA), a
olid drug matrix on a handle. More recently an intranasal
entanyl spray (INFS; Instanyl, Nycomed, Zurich, Switzerland),
n oral transmucosal fentanyl buccal tablet (FBT; Effentora,
ephalon), and a sublingual fentanyl tablet (Abstral®, Orexo
B, Uppsala, Sweden) have become available. All fentanyl
roducts are indicated for the treatment of BTCP in adult pa-
ients who receive maintenance opioid therapy for theirhronic cancer pain. In placebo-controlled trials, OTFC, FBT,
nd INFS were all found to be effective analgesics with rapid
ain relief for the treatment of BTCP [14–17]. OTFCwas shown
o provide greater reduction in pain intensity and increased
ain relief compared withmorphine [18]; however, in a recent
andomized controlled trial (RCT), more patients attained
aster pain relief with INFS compared with OTFC [19].
Decision making in health care requires robust informa-
ion on the comparative cost-effectiveness of new and exist-
ng treatments. Mixed treatment comparisons (MTCs) provide
means to evaluate competing health-care interventions in
he absence of direct head-to-head trials, and are becoming
ncreasingly valuable in economic evaluation [20–22].We con-
ucted a Bayesian MTC of INFS, OTFC, FBT, and normal-re-
ease morphine. Six RCTs were eligible for inclusion in this
eta-analysis: INFS versus placebo [17], INFS versus OTFC
19], FBT versus placebo (n2) [15,16], OTFC versus placebo
14], and OTFC versus morphine sulphate immediate release
MSIR) [18]. In this MTC, INFS provided greater reduction in
ain for all time points before 60 minutes versus OTFC and all
ime points before 45 minutes versus FBT [23].
The results of this MTC were used as the basis of the eco-
omic evaluation, which compares the cost-effectiveness of
NFS, OTFC, and FBT for the treatment of BTCP in a Swedish-
ased model using a payer perspective.
Methods
A decision-analysis model was developed to estimate the
cost-effectiveness of INFS, OTFC, and FBT for the treatment of
BTCP. Sublingual fentanyl tablet was excluded because there
were insufficient clinical trial data. Normal-release morphine
was also excluded because it is not indicated for BTCP. For
INFS, OTFC and FBT, the expected reductions in pain intensity
(PI) of BTCP episodes were translated into cost savings and
gains in quality-adjusted life years (QALYs).
Model concept
The basic concept of the model for measuring BTCP that was
avoided with treatment is shown in Figure 1. This includes a
defined level of background pain and number of BTCP epi-
sodes per day.
Without treatment, the PI of BTCP decreases over the
course of the episode. With treatment, the PI of the BTCP ep-
isode decreases more rapidly, with the total area under the
curve (AUC) during the episode (representing the total BTCP
experienced) being reduced. The area between the PI curves
for treatment and placebo reflects the amount of BTCP
avoided by the intervention. Assuming a certain number of
episodes per day, the percentage BTCP avoided with treat-
ment can be calculated for a defined time horizon.
Model inputs and assumptions
The patient population for the decision model was assumed to
be similar to those reported in the sixRCTs in theMTC.Theseare
patients whose background pain before the start of a BTCP epi-
276 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 7 4 – 2 8 1sode was adequately controlled by opioid treatment and re-
ported to be of no more than moderate severity (4 on a 0 [no
pain] to 10 [worst pain imaginable] numerical rating scale [NRS],
a well established scale to measure pain [24–26]). For the model
base case, background PI was set at 2. In trials, the number of
BTCP episodes ranged from one to four per day, so a value of 3
was used for the base case. It was also assumed that all BTCP
episodes were 1 hour in duration. The majority of patients with
BTCPhaveadvanced-stagecanceranda1-year timehorizonwas
assumed tobe adequate,with a life expectancyof 180days being
used for the base case scenario. Effects and costs were not dis-
counted because the time horizon did not exceed 1 year.
Efficacy data was obtained from six RCTs, identified by a
systematic literature review, and analyzedwith anMTCmeta-
analysis [23]. Details on the six different RCTs — study design,
number of randomized patients,main results regarding pain in-
tensity difference, and limitations — can be found in Table A1
in the Appendix at: doi:10.1016/j.jval.2010.09.007. All studies
were randomized, double-blind crossover trials, except the
trial by Mercadante et al. [19], which was a randomized, open-
label crossover trial.
The MTC provided estimates of the reduction of PI during
BTCP episodes in the absence of treatment [23], based on the
four studies with a placebo arm [14–17] (Fig. 2). Studies re-
Fig. 1 – Model concept. Pain intensity (PI) courses for two tre
shown, where treatment 1 is more efficacious than treatmen
BTCP experienced upon treatment during the episode. The d
treatment and the PI course with treatment reflects the amo
avoided by treatment 1 is greater than that of treatment 2.corded PI on a 0 to 10 NRS, and a pooled estimate was calcu-latedwith a fixed effectmodel. The PI difference (PID) for INFS,
OTFC and FBT relative to placebo was then estimated for dif-
ferent time points after the start of the BTCP episode (Fig. 2). In
Kress et al. [17], the PID for INFSwas reported for 10, 20, and 40
minutes, whereas PID was reported for every 15 minutes in
OTFC and FBT trials. To accommodate this difference in time
nts during a breakthrough cancer pain (BTCP) episode are
For both treatments the light grey area represents the total
grey area between the PI course in the absence of
of BTCP avoided by the treatment. The amount of BTCP
Fig. 2 – Pain intensity levels during a breakthrough cancer
pain (BTCP) episode with placebo, oral transmucosal
fentanyl citrate (OTFC), fentanyl buccal tablet (FBT), andatme
t 2.
ark
untintranasal fentanyl spray (INFS).
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277V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 7 4 – 2 8 1points, INFS averages at 10 and 20 minutes and at 20 and 40
minutes were used to estimate the 15- and 30-minute time
points, respectively. In Mercadante et al. [19], the PID for INFS
was reported for 5-, 10-, 15-, 20-, 30-, and 60-minute time
points. The INFS average at 30 and 60 minutes was used to
estimate the 45-minute time point.
In the clinical trials [14–19], the PI during the BTCP episode
did not always return to the background PI level within 60
minutes (see Fig. 2). In the absence of data beyond 60minutes,
PI curves were cut-off at this time point and background PI
level was assumed.
Utilities and QALYs
Utilities were incorporated into the model in order to estimate
QALYs for a specific PI course as well as the QALY gain by treat-
ment. In theabsenceof publishedutility values for BTCP, adirect
utility elicitation study was performed using a time trade off
(TTO) approach [27]. Utility values were generated for a hypo-
thetical patient with advanced stage cancer, with an initial PI of
6 at the start of a BTCP episode, background PI of 2, and three
BTCP episodes per day, corresponding to the patient population
in the model base case. Eight profiles were generated, each rep-
esented a possible course of PI over a 1-hour BTCP episode. The
rofiles ranged from a PI trajectory that changed little over the
uration of an episode (profile 1, defined as PI4 at 30 minutes
ndPI4at 1hour), to aPI trajectory that reducedquickly (profile
, defined as PI 3-3.9 at 5 min and PI 2-2.9 at 1 hour). Variants of
aseline characteristics for one profile (profile 2, defined as PI4
t 30 minutes and PI 3-3.9 at 1 hour) were tested to evaluate the
ensitivity of the utility estimates to differences in background
I, BTCP episode frequency, and PI at episode start.
The TTO exercise was conducted in a sample of 99members
f the United Kingdom general public. To derive utility esti-
ates, subjectswere askedwhether theywould rather spend 10
ears in each PI profile followed by death, or less than 10 years in
ull health and then death, with the time in full health varied
ntil a point of indifference was reached. To avoid question or-
er effects, the order inwhich the PI profileswere presentedwas
aried. The utility of each PI profile was then derived on an in-
erval scale from 0 to 1 using the following equation:
i time in full health ⁄ time in PI profile i; with iPI profile.
The mean utilities for all the PI profiles were logically or-
ered, ranging from 0.348 for the PI profile with the slowest PI
esolution (profile 1), to 0.679 for the profile with fastest reso-
ution (profile 8). The utility estimates for the PI profile 2 vari-
nts did not significantly alter themean utility for that profile.
ecause the eight PI profiles could not represent all possible
ourses of PI, a mathematical function (linear ordinary least
quares regression: utility  –0.1237*AUC  0.9536; R2  0.93)
as used to derive a relationship between utility and each
ossible AUC in the model.
Resource use and costs
Drug acquisition costs and costs for other health-care re-
source use (general practitioner [GP] visits, home care, andhospital stay) were included in the model. Drug acquisition
costs were based on 2008 Swedish pharmacy selling prices
[28]. OTFC is priced on a per treatment basis (€9.3 [Euros],
Swedish krona [SEK] 103.57 per BTCP dose). INFS was not
available in 2008, but has been launched since then at price
parity with OTFC. Thus, the same cost for INFS and OTFC per
BTCP episode was used in the model. FBT is not currently
available in Sweden so the cost was estimated based on the
United Kingdom, where it is priced approximately 14% less
than OTFC (€8.1, SEK 89.47).
A review of the literature found only a single study on the
impact of BTCP on health-care resource consumption. This
was a US telephone survey in which resource use (GP visits,
emergency room [ER] visits, and hospital admissions) were
compared for patients with and without BTCP [11]. Annual
probabilities of resource consumption as well as the fre-
quency of usewere reported, aswas the average length of stay
(LOS) per hospitalization. These data were validated by clinical
experts as applicable to the Swedish situation, althoughERvisits
were substituted with specialized home care (resource use and
costs assumed to be similar). Unit costs for Sweden were deter-
minedas €76 (SEK845)perGPvisit, €196 (SEK2182)perhomecare
visit, and €370 (SEK 4110) per hospital inpatient day (Södra Sam-
erkansnämnden price list, 2007). Unit costs display cross-re-
ional variation in Sweden, and a conservative approach was
aken in the current model by using the lowest reported costs
Malmö University Hospital, ward day). Using these unit costs,
he total costs of resource consumption were calculated. It was
ssumed that the resource consumption of patients with BTCP
eceiving placebo (i.e., no active treatment) was equivalent to
hat of patients with BTCP from the US survey. It was also as-
umed that the reduction in resource use had a linear relation-
hip with the percentage of BTCP avoided.
Direct non-medical costs (e.g., travel to hospital) are not
art of the payer perspective and therefore not modeled.
ndirect non-medical costs were not included either be-
ause it was assumed patients with BTCP would not have
dditional productivity loss or other non-medical opportu-
ity costs, given that they were unlikely to be in employ-
ent because of the advanced stage of their underlying dis-
ase. It was also assumed that any indirect medical costs
ere more likely to be attributable to cancer rather than
TCP.
An expert meeting with four independent Swedish physi-
ian-specialists in geriatrics, palliative care, and anesthesiol-
gy (two clinical experts) was held to validate the concepts
nd assumptions underlying the model and the data regard-
ng resource use.
Model outcomes
Outcome parameters were percentage of BTCP avoided, drug
costs, costs for resource use (GP visits, specialized home care,
and hospital stay), and QALYs gained. For the current model,
the primary estimate for cost-effectiveness was the incre-
mental cost per QALY gained.
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In addition to the base case scenario (background PI 2, three
BTCP episodes/day, time horizon 180 days, price of OTFC and
INFS assumed to be equal), alternative scenarios were also
considered. These were the same as above but with either
(a) background PI  3, or (b) including drug costs only.
Probabilistic sensitivity analysis
Probabilistic sensitivity analysis (PSA) allows for multiple un-
certainty across the input parameters to be assessed (unlike
one-way sensitivity analysis which only assesses the impact
of uncertainty for each input separately). In this model,
sources of parameter uncertainty were identified and charac-
terized as probability distributions. Parameters and distribu-
tions of the variables included in the PSA are summarized in
Table 1. A distribution of the (incremental) costs and benefits
(QALYs) was determined by sampling a value from each input
parameter distribution, calculating the results with themodel
and repeating this process 1000 times. Results are presented
with a point estimate and 95% uncertainty intervals (95% UIs).
Table 1 – Model parameters and distributions applied for t
Parameter Mean Unce
BTCP episodes per day 3
Background pain level 2
Efficacy
INFS
15 mins
30 mins
45 mins
60 mins
1.66
1.95
1.95
1.94
OTFC
15 mins
30 mins
45 mins
60 mins
0.42
1.01
1.32
1.52
FBT
15 mins
30 mins
45 mins
60 mins
0.51
0.96
1.41
1.67
Utility uncertainty
Slope
Intercept
0.12
0.95

Resource use (no BTCP)
Probability of GP visit
Probability of home care
Probability of hospitalisation
Length of hospital stay (days)
0.37
0.22
0.22
4.10
Resource use (BTCP)
Probability of GP visit
Probability of home care
Probability of hospitalisation
Length of hospital stay (days)
0.56
0.33
0.37
7.10
BTCP, breakthrough cancer pain; FBT, fentanyl buccal tablet; GP, gene
fentanyl citrate.
* Least squares mean used: correlation between both utility uncertaUncertainty intervals reflect confidence intervals ofmodel pa- rameters and also uncertainty for parameters based on expert
opinion.
Results
INFS, OTFC, and FBT were all superior to placebo, with the
percentage of total BTCP avoided reported as 55% with INFS
(95% UI 46%–68%), 29% with OTFC (95% UI 22%–38%), and 31%
with FBT (25%–39%) (Table 2).
Total costs for all treatments are reported in Table 2. For all
treatments, approximately 90% of overall costs were attribut-
able to drug acquisition. For the placebo arm, the majority of
the costs associatedwith resource usewere related to hospital
stay (81% of total costs).
In the base case analysis, INFS dominates OTFC (Table 3).
INFS is expected to avoid an additional 25% of BTCP compared
with OTFC, corresponding to a cost savings of €174 (SEK 1932)
nd a 0.046 QALY gain. Despite the uncertainty in the source
ata, the PSA shows there is a more than 99% probability that
NFS is cost-effective relative to OTFC. For a willingness-to-pay
WTP) of €45,000 (SEK 500,000), a generally accepted maximum
enchmark value for a QALY gained in Sweden [29], there is a
robabilistic sensitivity analysis.
ty range Reference Distribution type
3.75 [23] Normal
2.5 [23] Normal
[23] Normal
1.95
2.27
2.39
2.41
0.79
1.45
1.82
2.10
0.73
1.30
1.75
2.04
0.10
1.03
Calculation
*
Normal
0.47
0.31
0.31
4.92
[11]
[11]
[11]
Assumption
Beta
Beta
Beta
Normal
0.64
0.40
0.44
8.52
[11]
[11]
[11]
Assumption
Beta
Beta
Beta
Normal
ractitioner; INFS, intranasal fentanyl spray; OTFC, oral transmucosal
arameters has been taken into account.he p
rtain
2.25–
1.5–
1.38–
1.63–
1.50–
1.47–
0.04–
0.57–
0.82–
0.95–
0.29–
0.62–
1.07–
1.30–
0.14–
0.88–
0.27–
0.14–
0.14–
3.28–
0.49–
0.26–
0.29–
5.68–
ral p99%probability that INFS is themost cost-effective intervention.
pc
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priced 14% less, INFS is expected to have higher costs but
greater efficacy than FBT. An additional 24% of BTCP is
avoided, resulting in a QALY gain of 0.043 (Table 3). The cost
per QALY for INFS versus FBT is estimated at €12,203 (SEK
135,585). At a WTP of €45,000 (SEK 500,000), there is a 99%
robability that INFS is cost-effective compared with FBT.
INFS dominates when compared with OTFC and is more
ost-effective than FBT in a scenario that assumes a higher
ackground PI (3 rather than 2) (Table 3).When only drug costs
re compared, INFS still dominates OTFC and is more cost-
ffective than FBT because of the additional QALYs gained.
Discussion
The objective of this study was to evaluate the cost-effec-
tiveness of INFS with OTFC and also FBT for the treatment of
BTCP in Sweden. On the basis of this model, and assuming
price parity, INFS was dominating OTFC, provided cost sav-
ings and an increase in QALYs, and was more cost-effective
than FBT.
Table 2 – Model outcomes and cost estimates by treatment
Placebo
Model outcomes
% BTCP avoided versus placebo —
QALYs 0.167 (0.148, 0.183)
Cost estimates
Drug acquisition costs 0
GP costs €93 (78, 109)
Home care costs €68 (53, 85)
Hospital stay costs €715 (516, 950)
Total resource use costs €877 (680, 1112)
Total costs €877 (690, 1112)
BTCP, breakthrough cancer pain; FBT, fentanyl buccal tablet; GP, gene
fentanyl citrate; QALYs, quality-adjusted life years.
All costs over 180 days. 1 SEK  €0.09.
Table 3 – Cost-effectiveness of INFS compared with OTFC a
Incremental
costs, (% UI)
Increm
BTCP a
(95%
Base case scenario vs OTFC €174 (276, 98) 25% (17
Alternative scenario 1:
Background PI  3
€262 (486, 134) 38% (23
Alternative scenario 2:
Drug costs only
0 (0, 0) 25% (16
Base case scenario vs FBT €523 (432, 593) 24% (16
Alternative scenario 1:
Background PI  3
€441 (237, 554) 36% (22
Alternative scenario 2:
Drug costs only
€685 (685, 685) 24% (16
BTCP, breakthrough cancer pain; FBT, fentanyl buccal tablet; INFS,
fentanyl citrate; PI, pain intensity; QALYs, quality-adjusted life years
INFS performs better thanOTFC (incremental QALY 0.046) but increm
are not taken into consideration. Because incremental costs are the
1 SEK  €0.09. Dominant means cost-saving and more effective.Efficacy data in this model were derived from an MTC
meta-analysis of six RCTs in which INFS provided greater re-
duction in pain 15 minutes after administration than either
OTFC or FBT. This greater efficacy of INFS was maintained for
all time points before 60 minutes versus OTFC and all time
points before 45minutes versus FBT [23]. The effect of normal-
release morphine was similar to placebo for all time points
before 45 minutes after administration.
Although widely used, normal-release morphine is not in-
dicated for the treatment of BTCP and its slow onset of action
and extended duration of effect make it an unsuitable choice
for themajority of BTCP episodes [13]. Thus, despite the avail-
ability of low-cost generics, normal-release morphine is not
an ideal option for the effective treatment of BTCP.
When there is insufficient direct evidence from compara-
tive RCTs, a formal indirect comparison provides another
method for obtaining data on the relative efficacy of compet-
ing interventions. MTC is a method of indirect comparison
that combines both direct and indirect evidence and is partic-
ularly useful in the context of cost-effectiveness analysis and
medical decision making [20–22]. However, the validity of the
approach depends on the internal validity and similarity of
the base case scenario.
alue (95% uncertainty intervals)
INFS OTFC FBT
(46%, 68%) 29% (22%, 38%) 31% (25%, 39%)
6 (0.251, 0.281) 0.220 (0.203, 0.235) 0.223 (0.209, 0.237)
€5034 €5034 €4348
(36, 59) €69 (57, 82) €68 (56, 81)
(34, 54) €55 (44, 68) €55 (43, 67)
(289, 532) €550 (396, 716) €540 (398, 704)
(375, 629) €674 (514, 845) €662 (508, 828)
(5408, 5663) €5708 (5548, 5878) €5011 (4832, 5176)
ractitioner, INFS, intranasal fentanyl spray; OTFC, oral transmucosal
BT.
l %
ed
Incremental
utility (QALY)
(95% UI)
Costs per
BTCP
avoided
Cost per
QALY
gained
%) 0.046 (0.029, 0.064) Dominant Dominant
%) 0.046 (0.029, 0.066) Dominant Dominant
%) 0.046 (0.029, 0.065) NA NA
%) 0.043 (0.029, 0.059) €2216 €12203
%) 0.043 (0.029, 0.059) €1242 €10293
%) 0.043 (0.030, 0.059) €2902 €15979
nasal fentanyl spray; NA, not applicable; OTFC, oral transmucosal
ncertainty interval.
costs are the same since drug costs are similar and resource use costs
, an ICER cannot be calculated. INFS is still the preferred treatment.for
V
55%
0.26
€49
€44
€407
€500
€5534
ral pnd F
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void
UI)
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280 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 7 4 – 2 8 1the included trials [30]. Although the six trials included in this
MTC appear sufficiently similar in patient characteristics and
study designs for clinically meaningful conclusions to be
drawn, unknown factors may have biased indirect compari-
sons. Because of the limited number of studies included in the
model, any heterogeneity of treatment effects that may be
indicative of bias cannot be fully assessed. However, the re-
sults of the MTC are consistent with those of the randomized
head-to-head comparative trial of INFS and OTFC [19], on
which it is in part based, indicating the clinical validity of its
findings. In this case, the use of an MTC incorporates and
extends beyond the findings of the direct comparative trial of
INFS and OTFC by including additional data on the interven-
tions from other studies, as well as comparison with placebo.
The utility estimates in themodel were based on establish-
ing a relationship between PI level and a utility score. In order
not to overload the participants in the TTO exercise, it was
decided that utilities for a maximum of eight PI profiles (and
three variants of profile 2 to evaluate differences in back-
ground PI, episode frequency, and PI at episode start) would be
generated, resulting in a range of utilities from 0.348 to 0.679.
However, this does not represent all possible PI profiles that
could exist for a BTCP episode. A regressionmodelwas used to
estimate the cumulative utility andQALYassociatedwith area
under the curve for the BTCP experiencedwith each treatment
option in the model.
The TTO method used to generate utilities is a well estab-
lished method [27]. There is a difference between the utility as-
sessment (10 years) and the time horizon in the model (1 year).
Ten years is an appropriate timescale for a trading exercise
in cancer patients completed by members of the general pub-
lic, i.e., to enablemeaningful trade-offs between time spent in
the health state in question and longer time in perfect health
in order to derive a utility that can then be applied to the
episodes of breakthrough pain over the course of a year. Al-
though the study was performed in a UK population, the sub-
jects represented a cross section of the public froma European
country whose values and preferences can be assumed to be
similar to those in Sweden. There are no other available utili-
ties for BTCP, but utilities for conditions where pain is a large
component are in a similar range. For example, UK population
utilities for fibromyalgia have been estimated to be in the
range of 0.45 to 0.82 [31], and values associated with pain have
been reported for patients with severe rheumatoid arthritis
with 0.65 for a PI of 2, and 0.45 for a PI of 6 [32].
A possible limitation with this model is the lack of published
data on the resourceuseof BTCP. For the currentmodel,weused
data from theUS study by Fortner et al [11], which compared the
level of resourceuseof cancer patientswithandwithoutBTCP. It
is important to note that this was a retrospective observational
study for which data were collected through telephone inter-
views. Suchanobservational studycanbebiased for anumberof
reasons, including selection bias (participation in the survey
might have been associated with the level of resource use), in-
formation bias (only three types of resource usewere identified),
and recall bias (recollection might be related to BTCP). In addi-
tion, it was assumed that patients with BTCP in the survey by
Fortner et al. [11] were equivalent to the non-treated patients in
he currentmodelwith regard to resource use, and that resourcese displayed a linear relation to the percentage of BTCP
voided. Despite this potential bias, both the resource use data
nd the assumptionsmadewere validated by independent clin-
cal experts for the Swedish setting. Furthermore, the actual im-
act of resource use in the model is limited, because 90% of the
otal costs are related todrug acquisition costs. In the scenario in
hich resource use costs were excluded and only drug costs
ere considered, INFS remained the more cost-effective treat-
ent option compared with OTFC or FBT.
In addition to INFS, several other new fentanyl formula-
ions for the treatment of BTCP have recently been launched
r are at late stages of development. Oral transmucosal FBT
Effentora) is available in some European countries, but is not
et available in Sweden.
FBTwas included in themodel on the basis of pricing in the
nited Kingdom. Sublingual fentanyl citrate (Abstral) is avail-
ble in Sweden, butwas not included in theMTConwhich this
odel was based because there was only limited clinical data
vailable (its approval was primarily based on pharmacoki-
etic data). Other fentanyl products, including a bioerodible
ucoadhesive (BEMA) fentanyl disc and a dry powder fenta-
yl inhaler, are also likely to be available in the near future.
ike sublingual fentanyl citrate, these products were not in-
luded in the current model because clinical trial data were
ot available, but may need to be considered in the future.
Safety was not included in the model. This was primarily
ecause no differences in adverse events were expected given
hat the active ingredient in the interventions (fentanyl) is the
ame. In addition, patients who experience adverse effects
ay have been withdrawn from trials before randomization
ecause all trials included an initial titration phase to deter-
ine the most effective tolerable dose. A further reason that
afety was not included is that it is difficult to distinguish
dverse effects related to treatment of BTCP from those attrib-
table to opioid treatment for background pain.
Conclusions
In conclusion, treatment with INFS provides a faster onset of
pain relief and greater reduction in BTCP than achieved with
OTFC or FBT. This improvement in analgesic efficacy with
INFS seems to translate into savings in health-care resource
use and medical costs as well as improved quality of life for
patients with BTCP. Based on this model analysis, INFS can be
considered a cost-effective option compared with OTFC and
FBT for the treatment of BTCP in Sweden.
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